Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

rare disease unit

This page shows the latest rare disease unit news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets EU OK for Ablynx flagship drug Cablivi

Sanofi gets EU OK for Ablynx flagship drug Cablivi

The new drug is the first new product to come from Sanofi’s push into rare disease therapies and specifically rare blood disorders, which was also behind its $11.6bn acquisition ... s Genzyme rare disease unit.

Latest news

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Pfizer Rare Disease Research Unit. ... Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

  • Dupixent bounce-back helps stem diabetes declines at Sanofi Dupixent bounce-back helps stem diabetes declines at Sanofi

    Rare disease unit Genzyme had a good quarter, with sales up 6% to 743m, but vaccines business Sanofi Pasteur was under pressure with sales falling almost 16% to 811m due to ... hoping that the 3.9bn takeover of antibody specialist Ablynx and lead rare

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab ... In the last few

  • Sanofi warns of difficult few months as diabetes sales slump Sanofi warns of difficult few months as diabetes sales slump

    The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who ... Revenues were however fairly flat if exchange

  • P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

    P&G has won the unit despite interest from other partners, including Nestle, Novartis and reportedly Mylan, which as recently as last week was said to be in advanced negotiations. ... In the last few weeks Sanofi has sold its European generics business

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Focus on Rare Diseases

    Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise ... Within this unit, Lucid

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Quick links

Infographics

Multimedia